PROTECT Pregnancy Study: An Exploratory Study of Self-reported Medication Use in Pregnant Women
IMI PROTECT - Work Package 4 - Pregnancy Study: An Exploratory Study of Self-reported Medication Use in Pregnant Women
Study was a non-interventional, prospective study of pregnant women who agreed to provide information about their medication use and certain lifestyle factors on a periodic basis throughout their pregnancy. Volunteers were recruited by measures such as placement of pamphlets near pregnancy test kits in pharmacies and by links from carefully selected websites and social networking sites. Subjects were invited to learn about the study either through visiting the study web site or phoning a telephone number where a recorded message described the study and invite eligible women to register for participation.
Participants were asked whether they prefer to provide data via the internet or by interactive voice response system (IVRS).
Data were collected in the predominant natural languages of the four study countries: Denmark, the Netherlands, Poland, and the United Kingdom (UK).
Data were collected on use of prescription and non-prescription medication, as well as on use of herbals and homeopathic medications. More information was be collected from women who provided their response over the internet than by phone, in order to best utilize the full capacity of internet- based data collection.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
The PROTECT Pregnancy Study was designed to pilot direct-to-patient data collection methods for use in postmarketing surveillance into the foetal effects of maternal medication use in pregnancy. This study which recruited women between October 2012 and January 2014 explored whether women in participating EU countries were willing to provide information via the internet to enable prospective collection of medication exposure data and information about other life style factors during pregnancy. The study's main objective was to assess the extent to which data collected directly from pregnant women via the Internet and an interactive voice response system (IVRS) would provide information on medication use and other potential risk factors throughout pregnancy that is suitable for research purposes.
Pregnant women were recruited for the study using a variety of methods and were asked about use of medications, alcohol and tobacco, recreational drugs, herbals and other factors that could negatively affect birth outcome. The pilot study revealed that women would indeed volunteer to provide information on medication and lifestyle factors during pregnancy, with 2521 women enrolling from four countries over 8-18 months. The four countries include the United Kingdom (UK), The Netherlands (NL), Denmark (DK) and Poland (PL). Of those who enrolled in the PROTECT pregnancy study, only 2066 provided any data, with all but one providing data via internet.
Tipo di studio
Iscrizione (Effettivo)
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
It was initially planned that a minimum of 1400 pregnant women (5600 women total, study-wide) will be recruited from each of the four participating countries: Denmark, the Netherlands, Poland, and the United Kingdom.
From this number of 1400 participants per country, a limit of 200 women (800 women total, study-wide) would have contributed data via the phone recording system while 1200 would have participate online.
Descrizione
Inclusion Criteria:
- Women who identify themselves as pregnant;
- Access to the internet or telephone for providing data;
- Willingness to provide either their e-mail address or telephone number for automated follow-up reminders;
- Primary residence in one of the four participating EU countries: Denmark, the Netherlands, Poland, and the United Kingdom;
- Proficiency in the predominant natural language of their country of residence : Danish, Dutch, Polish, or English.
Exclusion Criteria:
- Women below the age for providing consent.
- Women who are not resident in one of the four participating countries.
- Women in Denmark who are not willing to provide their civil registration number
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Pregnancy Outcome
Lasso di tempo: At pregnancy end (delivery or termination)
|
Patient-reported pregnancy outcome is assessed upon pregnancy termination, stillbirth or live birth, recorded from point of enrollment through 30 days after expected date of confinement.
No time to event analyses are performed since the study purpose is to compare self-reported events, including pregnancy outcome, with those same events recorded in electronic medical records and the national pregnancy register in Denmark.
|
At pregnancy end (delivery or termination)
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Nancy Dreyer, MPH, PhD, Quintiles Real-World & Late Phase Reasearch, Cambridge, USA
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- PROTECT_WP4_v8Mar12
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .